Suzhou Hekai Biotech

Suzhou Hekai Biotech is a China-based biotechnology company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies, with a primary focus on molecular glues. The company leverages its proprietary Glue-Engine platform to identify and optimize small molecules that induce the degradation of previously undruggable disease-causing proteins. Their pipeline primarily targets hematological malignancies and solid tumors through the degradation of transcription factors and other key regulatory proteins. Founded by industry veterans with expertise in protein degradation from companies like Celgene and Bristol Myers Squibb, Hekai Biotech aims to provide innovative treatment options for patients with high unmet medical needs. The company is headquartered in the Suzhou Industrial Park and has received significant backing from leading venture capital firms. Their lead program, HK-001, is a molecular glue degrader targeting GSPT1 for various solid tumor indications.